CryoCor European Recall Drops Sales As Firm Submits Atrial Flutter PMA
This article was originally published in The Gray Sheet
Executive Summary
CryoCor does not believe a European recall of its Model 1200 cryoablation device will hamper efforts to secure PMA approval for the unit's successor, CryoBlator, in the U.S
You may also be interested in...
Cryoablation Device PMA For Atrial Flutter To Be Financed With IPO Proceeds
CryoCor will use approximately 35% of the $31.7 mil. it expects to net from an initial public offering to continue product development and complete a Phase II clinical trial of cryoablation to treat atrial flutter
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.